Dato Dr. Kim Tan is the Chairman of SpringHill Management, a private fund management company specialising in biotech and social venture capital investments. He is a partner of several social impact funds including Inqo Investments (South Africa), Springhill Equity Partners (US), Novastar Ventures (Kenya) and Garden Impact Investment (Singapore). He is the co-founder of the Transformational Business Network and is ’on the advisory boards of the John Templeton Foundation, Templeton Religion Trust and the Johnson & Johnson Impact Ventures. He was the founder chairman of NCI Cancer Hospital (Malaysia) and the inventor of sheep monoclonal antibodies. He is a Pro-Chancellor of Surrey University (UK), a board member of the Centre for Enterprise, Markets & Ethics (Oxford) and a Fellow of the Royal Society of Medicine (UK). He is a former board member of the Saracens Rugby Club, Surrey University and the APEC Life Science Innovation Forum.